Covered recipient · General Payments record
DAVID R ERB
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$2,239.15
143 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,239.15 | 143 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 3 of 3; records 101–143 of 143 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID R ERB
NPI 1952366478 · CMS profile ID 89023
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
SPARTANBURG, SC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–143 of 143 matching records. This page contains 43 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1952366478?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID R ERB, NPI 1952366478, CMS profile ID 89023. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–143 of 143 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952366478?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). DAVID R ERB, NPI 1952366478, CMS profile ID 89023. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–143 of 143 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952366478?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- DAVID R ERB, NPI 1952366478, CMS profile ID 89023, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–143 of 143 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1952366478?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
143 matching records · $2,239.15 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–143 of 143.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Electromed, Inc. | $4.63 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849601815 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.99 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834342555 | CMS |
| GlaxoSmithKline, LLC. | $11.24 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803191863 | CMS |
| GlaxoSmithKline, LLC. | $11.53 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802797757 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.03 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834343233 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12.65 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763659158 | CMS |
| Grifols USA, LLC | $17.98 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846762167 | CMS |
| Janssen Pharmaceuticals, Inc | $13.38 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788854765 | CMS |
| Electromed, Inc. | $18.94 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849601787 | CMS |
| GENZYME CORPORATION | $21.15 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843438511 | CMS |
| Mylan Specialty L.P. | $28.37 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965407737 | CMS |
| Janssen Pharmaceuticals, Inc | $13.84 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788854777 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $10.23 | 03/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819920995 | CMS |
| Electromed, Inc. | $16.62 | 03/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849601689 | CMS |
| GlaxoSmithKline, LLC. | $10.30 | 03/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802878671 | CMS |
| GlaxoSmithKline, LLC. | $12.12 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801604475 | CMS |
| Novartis Pharmaceuticals Corporation | $17.72 | 03/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812671765 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $9.42 | 03/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763659160 | CMS |
| Grifols USA, LLC | $11.95 | 03/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846750735 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.89 | 03/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834332439 | CMS |
| United Therapeutics Corporation | $17.96 | 03/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839126457 | CMS |
| Gilead Sciences, Inc. | $20.10 | 03/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848191225 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.15 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763659162 | CMS |
| GENZYME CORPORATION | $20.07 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843438495 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.88 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834347671 | CMS |
| Sunovion Pharmaceuticals Inc. | $19.94 | 02/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821659893 | CMS |
| Electromed, Inc. | $9.14 | 02/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849601469 | CMS |
| Teva Pharmaceuticals USA, Inc. | $11.09 | 02/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839692857 | CMS |
| Electromed, Inc. | $19.83 | 02/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849601463 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.47 | 02/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763659164 | CMS |
| GlaxoSmithKline, LLC. | $10.48 | 02/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803091331 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.78 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819920993 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.49 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763659166 | CMS |
| Electromed, Inc. | $1.79 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849612131 | CMS |
| Electromed, Inc. | $1.79 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849613277 | CMS |
| GENZYME CORPORATION | $21.08 | 01/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843438489 | CMS |
| Electromed, Inc. | $9.45 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849612125 | CMS |
| Electromed, Inc. | $9.45 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849613271 | CMS |
| Janssen Pharmaceuticals, Inc | $11.10 | 01/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788854773 | CMS |
| GlaxoSmithKline, LLC. | $3.58 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802032256 | CMS |
| Grifols USA, LLC | $18.99 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846776777 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.82 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763659168 | CMS |
| AstraZeneca Pharmaceuticals LP | $114.91 | 01/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834318997 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,466,754.37 | 509 |
| PY2024 | Principal investigator | $2,201,737.32 | 367 |
| PY2023 | Recipient | $9,825.26 | 7 |
| PY2023 | Principal investigator | $1,674,628.38 | 1,560 |
| PY2022 | Recipient | $1,722.00 | 1 |
| PY2022 | Principal investigator | $1,047,846.77 | 797 |
| PY2021 | Recipient | $4,604.87 | 2 |
| PY2021 | Principal investigator | $405,371.19 | 20 |
| PY2020 | Recipient | $69,718.60 | 2 |
| PY2020 | Principal investigator | $491,750.29 | 44 |
| PY2019 | Principal investigator | $190,896.99 | 50 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
509 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Currax Pharmaceuticals LLC | $6,970.32 | 12/24/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242718368 |
| Principal investigator 1 | Seqirus USA Inc | $1,089.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185272402 |
| Principal investigator 1 | Seqirus USA Inc | $1,089.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273776 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279499 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279501 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279503 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279505 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279507 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279509 |
| Principal investigator 1 | Seqirus USA Inc | $47.60 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279911 |
| Principal investigator 1 | Seqirus USA Inc | $47.60 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279913 |
| Principal investigator 1 | Seqirus USA Inc | $47.60 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279915 |
| Principal investigator 1 | Seqirus USA Inc | $47.60 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279917 |
| Principal investigator 1 | Seqirus USA Inc | $47.60 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279919 |
| Principal investigator 1 | Seqirus USA Inc | $47.60 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279921 |
| Principal investigator 1 | Seqirus USA Inc | $47.60 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279923 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280065 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280067 |
| Principal investigator 1 | Seqirus USA Inc | $819.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280753 |
| Principal investigator 1 | Seqirus USA Inc | $819.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280755 |
| Principal investigator 1 | Seqirus USA Inc | $819.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280793 |
| Principal investigator 1 | Seqirus USA Inc | $819.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280795 |
| Principal investigator 1 | Seqirus USA Inc | $819.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280797 |
| Principal investigator 1 | Seqirus USA Inc | $819.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280799 |
| Principal investigator 1 | Seqirus USA Inc | $819.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280801 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281233 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281235 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281237 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281239 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281241 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281243 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281245 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281247 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281249 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281251 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281253 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281255 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281257 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281259 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281485 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281489 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281491 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281493 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281495 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281497 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281499 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281501 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281503 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281505 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281507 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281509 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281511 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281513 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281515 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281517 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281519 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281521 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281523 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281525 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281527 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281529 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281531 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281533 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281535 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281537 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281539 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281541 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281543 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281545 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281547 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281549 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281551 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281553 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281555 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281557 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281559 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281561 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281563 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281565 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281567 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281569 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281571 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281573 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281575 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281577 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281579 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281581 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281583 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281585 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281587 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281589 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281591 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281593 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281595 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281597 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281600 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281603 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281605 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281607 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281609 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281611 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281613 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281615 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281617 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281619 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281621 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281623 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281625 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281627 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281629 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281631 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281633 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281635 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281637 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185281639 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282131 |
| Principal investigator 1 | Verona Pharma, Inc. | $9,804.98 | 12/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891949 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,000.00 | 12/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891993 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273802 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273805 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273807 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273810 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273812 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273814 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273816 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273818 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273820 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273822 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273824 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273826 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273828 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273830 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273833 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273836 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273838 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273840 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273842 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273844 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273846 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273848 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273850 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273852 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273854 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273856 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273858 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273860 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273862 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273864 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273866 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273868 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273870 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273872 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273874 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273876 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273878 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273880 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273882 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273884 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273886 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273888 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273890 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273892 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273894 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273896 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273898 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273900 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273902 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273904 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273906 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273908 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273910 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273912 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273914 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273916 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273954 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273956 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273958 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273960 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273962 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273964 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273966 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273968 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274042 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274044 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274046 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274048 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274050 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274052 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274054 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274056 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274058 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274060 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274062 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274064 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274066 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274068 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274070 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274072 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274074 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274076 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274162 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274164 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274166 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274168 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274170 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274172 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274174 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274300 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 12/17/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763779 |
| Principal investigator 1 | ModernaTX, Inc. | $13,023.86 | 12/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002223 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,008.20 | 12/15/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800232 |
| Principal investigator 1 | ModernaTX, Inc. | $1,444.00 | 12/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012392 |
| Principal investigator 1 | ModernaTX, Inc. | $425.00 | 12/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012402 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 12/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683935 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683941 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 12/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763769 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763771 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $129.00 | 12/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763773 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34,001.00 | 12/01/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220800842 |
| Principal investigator 1 | Seqirus USA Inc | $1,709.60 | 11/21/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809811 |
| Principal investigator 1 | Seqirus USA Inc | $469.80 | 11/21/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809816 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $650.00 | 11/20/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242718292 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 11/19/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763777 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $11,684.68 | 11/19/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220998145 |
| Principal investigator 1 | Verona Pharma, Inc. | $36,288.78 | 11/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891947 |
| Principal investigator 1 | Verona Pharma, Inc. | $4,314.00 | 11/14/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891921 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $6,840.95 | 11/13/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242718248 |
| Principal investigator 1 | Verona Pharma, Inc. | $500.00 | 11/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232892007 |
| Principal investigator 1 | Seqirus USA Inc | $3,846.60 | 11/07/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809747 |
| Principal investigator 1 | Seqirus USA Inc | $1,057.05 | 11/07/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683917 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763767 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,300.00 | 10/30/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242718188 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 10/27/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763775 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,525.58 | 10/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232892005 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $6,969.97 | 10/14/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242718114 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 10/10/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220998143 |
| Principal investigator 1 | Verona Pharma, Inc. | $35,809.63 | 10/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891945 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 10/09/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | No dispute reported | 06/30/2026 | 1228738097 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,500.00 | 10/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192159862 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 10/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763765 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 09/24/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683873 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 09/24/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 09/24/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.66 | 09/24/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.32 | 09/24/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $459.54 | 09/24/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763763 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/22/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220801128 |
| Principal investigator 1 | Seqirus USA Inc | $1,183.50 | 09/22/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276680 |
| Principal investigator 1 | Seqirus USA Inc | $111.30 | 09/22/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276794 |
| Principal investigator 1 | Seqirus USA Inc | $177.19 | 09/22/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276798 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,809.60 | 09/18/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800230 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,500.00 | 09/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232892110 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,500.00 | 09/11/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220800840 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,007.72 | 09/10/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220998141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683827 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683829 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683831 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683833 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683837 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683839 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683841 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683843 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683867 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763755 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,400.00 | 09/01/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800228 |
| Principal investigator 1 | ModernaTX, Inc. | $93.96 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002193 |
| Principal investigator 1 | ModernaTX, Inc. | $540.00 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002205 |
| Principal investigator 1 | ModernaTX, Inc. | $200.00 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002207 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 08/26/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 08/26/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 08/26/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763761 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 08/21/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220998137 |
| Principal investigator 1 | Genentech, Inc. | $5,000.00 | 08/20/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211682234 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,400.00 | 08/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891865 |
| Principal investigator 1 | Verona Pharma, Inc. | $10,000.00 | 08/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232892138 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,199.90 | 08/06/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800226 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 08/05/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220998139 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683809 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683811 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683813 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683815 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683817 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683819 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683821 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763753 |
| Principal investigator 1 | Seqirus USA Inc | $2,000.00 | 08/01/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276876 |
| Principal investigator 1 | Seqirus USA Inc | $14,500.00 | 08/01/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276882 |
| Principal investigator 1 | Seqirus USA Inc | $27,126.40 | 08/01/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276890 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,917.00 | 07/31/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800224 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 07/28/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 07/28/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763759 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $391.52 | 07/25/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220813637 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 07/22/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220998135 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,672.70 | 07/22/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800222 |
| Principal investigator 1 | ModernaTX, Inc. | $8,960.00 | 07/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012398 |
| Principal investigator 1 | Genentech, Inc. | $5,110.00 | 07/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211682232 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,880.00 | 07/09/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800218 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,800.00 | 07/09/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800220 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683845 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683847 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683849 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683851 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683853 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683855 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683857 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683859 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683861 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683863 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763751 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 06/24/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683793 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 06/24/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683795 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $12,839.16 | 06/24/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717974 |
| Principal investigator 1 | ModernaTX, Inc. | $15,200.00 | 06/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012394 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $2,275.00 | 06/05/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717661 |
| Principal investigator 1 | ModernaTX, Inc. | $17,850.00 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012396 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683773 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683775 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683777 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683779 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683781 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683785 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683789 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683791 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 06/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763743 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 06/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763745 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 06/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763747 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Velocity Clinical Research-Gaffney | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220763749 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $7,386.60 | 05/28/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717904 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 05/27/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683801 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 05/27/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683803 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 05/27/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683805 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.04 | 05/27/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683807 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,400.00 | 05/27/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800214 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,125.00 | 05/27/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800216 |
| Principal investigator 1 | ModernaTX, Inc. | $152,000.00 | 05/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012384 |
| Principal investigator 1 | ModernaTX, Inc. | $264.93 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002191 |
| Principal investigator 1 | ModernaTX, Inc. | $67.00 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002195 |
| Principal investigator 1 | ModernaTX, Inc. | $165.64 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002201 |
| Principal investigator 1 | ModernaTX, Inc. | $1,057.68 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002209 |
| Principal investigator 1 | ModernaTX, Inc. | $291.83 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002213 |
| Principal investigator 1 | ModernaTX, Inc. | $925.86 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002215 |
| Principal investigator 1 | ModernaTX, Inc. | $6,044.48 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002217 |
| Principal investigator 1 | ModernaTX, Inc. | $7,318.68 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002219 |
| Principal investigator 1 | ModernaTX, Inc. | $5,750.92 | 05/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002225 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,000.00 | 05/15/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800212 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $64,880.42 | 05/09/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus | No dispute reported | 06/30/2026 | 1185540591 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,949.30 | 05/09/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800210 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683751 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 05/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683755 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683759 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683763 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683765 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683767 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683769 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683771 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500.00 | 05/01/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800206 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 05/01/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800208 |
| Principal investigator 1 | ModernaTX, Inc. | $1,520.00 | 04/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012388 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $697.13 | 04/24/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717789 |
| Principal investigator 1 | Genentech, Inc. | $3,200.00 | 04/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211682208 |
| Principal investigator 1 | Genentech, Inc. | $1,022.00 | 04/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211682212 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 04/23/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683797 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 04/23/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683799 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683731 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683737 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683739 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683741 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683743 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683745 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683747 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683749 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,665.40 | 03/26/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800204 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $325.00 | 03/20/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717259 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $20,865.00 | 03/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD | No dispute reported | 06/30/2026 | 1185540589 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $17,887.99 | 03/05/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683703 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683705 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683707 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683709 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683711 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683713 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683715 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683717 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683719 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683721 |
| Principal investigator 1 | ModernaTX, Inc. | $1,002.00 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012390 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 02/25/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683727 |
| Principal investigator 1 | Genentech, Inc. | $3,066.00 | 02/18/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211682200 |
| Principal investigator 1 | ModernaTX, Inc. | $600.00 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002197 |
| Principal investigator 1 | ModernaTX, Inc. | $800.00 | 02/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002211 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $240.50 | 02/06/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717223 |
| Principal investigator 1 | Genentech, Inc. | $5,244.00 | 02/06/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Ph III OLE of Astegolimab in COPD | No dispute reported | 06/30/2026 | 1211682198 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683681 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683683 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683685 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683687 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683689 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683691 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683693 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683695 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683697 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683699 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.50 | 02/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683701 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $481.00 | 01/30/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717193 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $70,392.76 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185540587 |
| Principal investigator 1 | ModernaTX, Inc. | $33,069.86 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002203 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,000.00 | 01/28/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800202 |
| Principal investigator 1 | Eli Lilly and Company | $1,892.00 | 01/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187891008 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 01/27/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.18 | 01/27/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683725 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,251.80 | 01/27/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800200 |
| Principal investigator 1 | ModernaTX, Inc. | $5,225.00 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012386 |
| Principal investigator 1 | ModernaTX, Inc. | $334.00 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253012400 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $37,633.60 | 01/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease | No dispute reported | 06/30/2026 | 1185540595 |
| Principal investigator 1 | ModernaTX, Inc. | $4,800.00 | 01/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002199 |
| Principal investigator 1 | ModernaTX, Inc. | $3,600.00 | 01/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253002221 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,833.50 | 01/21/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800198 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $40,123.80 | 01/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) | No dispute reported | 06/30/2026 | 1185540593 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277187 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277189 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277191 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277193 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277195 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277197 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277199 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277201 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277203 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277205 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277207 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277507 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277509 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277511 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277513 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277515 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277517 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277519 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277521 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277523 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277525 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277527 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277529 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277531 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277533 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277535 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277537 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277539 |
| Principal investigator 1 | Seqirus USA Inc | $1,088.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277541 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277565 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277567 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277569 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277571 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277573 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277575 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277577 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277579 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277581 |
| Principal investigator 1 | Seqirus USA Inc | $506.00 | 01/08/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185277583 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $90.00 | 01/06/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800196 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683663 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683665 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683667 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683669 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683671 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683673 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683675 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683677 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683679 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Vitalink Research-Gaffney | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220683729 |